Companies covered: Achieve Life Sciences (NASDAQ:ACHV), Pfizer, Inc. (NYSE:PFE), Biora Therapeutics Inc. (NASDAQ:BIOR), Rani Therapeutics Holdings Inc. (NASDAQ:RANI), Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX), Novo Nordisk A/S (NYSE:NVO), Catalent, Inc. (NYSE:CTLT), Gilead Sciences, Inc. (NASDAQ:GILD), Merck & Company, Inc. (NYSE:MRK), Bristol-Myers Squibb Company (NYSE:BMY), AstraZeneca PLC (NASDAQ:AZN), Eli Lilly and Company (NYSE:LLY), XOMA Corporation (NASDAQ:XOMA), Fortress Biotech, Inc. (NASDAQ:FBIO), Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), Lexaria Bioscience Corp. (NASDAQ:LEXX), Telix Pharmaceuticals Ltd. (OTCMKTS:TLPPF), IN8bio, Inc. (NASDAQ:INAB), DRI Healthcare Trust (OTCMKTS:DHTRF), Royalty Pharma plc (NASDAQ:RPRX), Argenx SE (ADR) (NASDAQ:ARGX), Amgen Inc. (NASDAQ:AMGN), Genmab A/S - ADR (NASDAQ:GMAB), Johnson & Johnson (NYSE:JNJ), Novartis AG (NYSE:NVS), Sanofi (NYSE:SNY), Lantheus Holdings Inc. (NASDAQ:LNTH), Janux Therapeutics Inc. (NASDAQ:JANX)), Cullinan Therapeutics Inc. (NASDAQ:CGEM), NewAmsterdam Pharma Company NV (NASDAQ:NAMS), PTC Therapeutics, Inc. (NASDAQ:PTCT), Dianthus Therapeutics Inc. (NASDAQ:DNTH), Axsome Therapeutics (NASDAQ:AXSM), Longboard Pharmaceuticals Inc. (NASDAQ:LBPH), Praxis Precision Medicines Inc. (NASDAQ:PRAX), Cidara Therapeutics Inc. (NASDAQ:CDTX), Omeros Corporation (NASDAQ:OMER), 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP), CompuMed Inc. (OTCMKTS:CMPD), MediWound Ltd. (NASDAQ:MDWD), Mesoblast Limited (NASDAQ:MESO), NanoViricides, Inc. (NYSEAMERICAN:NNVC), Neuren Pharmaceuticals Ltd. (OTCMKTS:NURPF), OSE Immunotherapeutics SA (EPA:OSE), Pasithea Therapeutics Corp. (NASDAQ:KTTA), Premier, Inc. (NASDAQ:PINC)
